Does the Presence of Dissociative Symptoms Affect the Response to Venlafaxine Treatment for Major Depression? An Open-Label, Prospective Study
Psychiatric Annals, cilt.52, sa.3, ss.119-125, 2022 (SSCI, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 52 Sayı: 3
- Basım Tarihi: 2022
- Doi Numarası: 10.3928/00485713-20220222-02
- Dergi Adı: Psychiatric Annals
- Derginin Tarandığı İndeksler: Social Sciences Citation Index (SSCI), Scopus, Psycinfo
- Sayfa Sayıları: ss.119-125
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Many psychiatric diseases may be ac-companied by dissociative symptoms and disorders. This study examined whether dissociative symptoms affect the response to venlafaxine treatment for major depressive disorder (MDD). The study included 40 patients who had a diagnosis of MDD according to Diagnostic and Statistical Manual of Mental Disorders (fifth edition) crite-ria. Venlafaxine was administered to each patient (37.5 mg to 150 mg daily) for 10 weeks. The researchers used the Beck Depression Inventory (BDI) and the Dissociation Questionnaire (DIS-Q) on cases with MDD at the beginning of the study. The researchers divided the patients into two groups according to DIS-Q scores and conducted the BDI again at the end of the 10-week period. The authors detected the difference between the values of decrease in BDI scores as a percentage. They found these values to be 48.03% ± 29.03 in the low DIS-Q group and 27.06% ± 32.91 in the high DIS-Q group. They also found a significant difference between the groups (z = –2.167; P = .030). This study showed that, in patients with MDD, intense dissociative experiences reduced the response to venlafaxine therapy.